Influenza Vaccination in Patients Living With HIV in the Northern Region (VACCIGRIPPE)

Influenza Vaccination in Patients Living With HIV in the Northern Region: An Observational Monocentre Study of Blankets, Modalities, Drivers and Brakes

Anyone living with the Human Immunodeficiency Virus (HIV) has an indication for annual influenza vaccination. (Vaccination schedule and vaccination recommendations 2019). Influenza is a viral infection that has a significant impact on the health care system. However, vaccination coverage in France is still insufficient with regard to the objectives set at 75% by the WHO and the European Commission. For the 2019-2020 seasonal influenza vaccination campaign, flu vaccination by volunteer pharmacists has become possible throughout the country. Studies that have estimated vaccination coverage among HIV-positive populations are rare and show very low rates.

Study Overview

• Status: Completed
• Conditions: HIV

Detailed Description

Cross-sectional study via a self-questionnaire given to all HIV-infected patients coming for a scheduled consultation as part of their HIV follow-up in the spring of 2020. Non-opposition letter given to the patient. Collection of data a posteriori from the medical file recorded in the eNadis patient file.

• Study Type: Observational
• Enrollment (Actual): 124

Contacts and Locations

Study Locations

• France
  • Tourcoing, France
    • Ch Tourcoing

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Any adult person living with HIV presenting for a follow-up consultation in the spring of 2020

Description

Inclusion Criteria:

• Any adult person living with HIV presenting for a follow-up consultation in the spring of 2020
• People who do not read French may participate if they wish with the help of a medical or paramedical staff member.
• Patient did not object

Exclusion Criteria:

• Minor patients
• Major under guardianship, curatorship, protected person

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
questionnaire influenza vaccine coverage	The objective of this questionnaire is to estimate the influenza vaccine coverage among PVVIH followed at the Tourcoing Hospital Center.	through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
modalities of influenza vaccination	To identify the modalities of influenza vaccination when it is carried out	through study completion, an average of 1 year
the drivers and disincentives to influenza vaccination	Estimate from patient reports the drivers and disincentives to influenza vaccination in a specific risk population.	through study completion, an average of 1 year

Collaborators and Investigators

• Sponsor: Tourcoing Hospital
• Investigators: Principal Investigator: Macha TETART, MD, Ch Tourcoing

Study record dates

Study Major Dates

• Study Start (Actual): April 10, 2020
• Primary Completion (Actual): September 30, 2020
• Study Completion (Actual): December 30, 2020

Study Registration Dates

• First Submitted: April 17, 2020
• First Submitted That Met QC Criteria: May 20, 2020
• First Posted (Actual): May 27, 2020

Study Record Updates

• Last Update Posted (Actual): January 26, 2021
• Last Update Submitted That Met QC Criteria: January 25, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: RIPH_2020_5

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No